Elan A. Cohen, Ph.D.
Hassman Research Institute, LLC

175 Cross Keys Road
Centennial Center, Bldg. 300 B
Berlin, NJ 08009

401 Route 73 North
30 Lake Center Executive Park, Suite 100
Marlton, NJ 08053

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Alliance Director
Tel. (916) 939-6696
Fax (208) 575-3169
Email: clinicaltrials@alliancesites.com

Site Contact:
Mitchell Hassman, MBA, Director of BD
Tel. (856) 753-7335 x 350
Fax (856) 306-6590
Email: mrhassman@hritrials.com

AFFILIATIONS:

Berlin Medical Associates
175 Cross Keys Rd, Suite 300A
Berlin, NJ 08009

Comprehensive Clinical Research
175 Cross Keys Road
Berlin, NJ 08009

EDUCATION:

2001 Counseling Psychology/Ph.D.
Indiana State University, Terre Haute, IN

1997 Counseling Psychology/M.A.
Ball State University, Muncie, IN

1995 Psychology/B.A.
The Ohio State University, Columbus, OH

INTERNSHIP:

Aug 2000 – Aug 2001 Pre- Doctorate Internship, Psychology, Counseling and Psychological Services, University of Pennsylvania, Philadelphia, PA

FELLOWSHIP:

Sept 2001 – Aug 2002 Post-Doctorate Psychology Fellow, Counseling and Psychology Services University of Pennsylvania, Philadelphia, PA

LICENSURE:

2006 – Present Licensed Psychologist
Pennsylvania License #: PS016067
New Jersey License #: 35SI00594700

PROFESSIONAL EXPERIENCE:

Principal Investigator, Psychometric Rater, Licensed Psychologist, Feb 2016 – Present
Hassman Research, Institute, LLC, Berlin, NJ

Director / Clinical Assessment Technologies, Feb 2014 – Feb 2016
Worldwide Clinical Trials, King of Prussia, PA

Associate Director of Operations, Clinical Trial Services Department, Aug 2013 – Jan 2014
MedAvante, Inc., Hamilton, NJ

Associate Director of Clinical Teams, Clinical Trial Services Department, Nov 2011 – July 2013
MedAvante, Inc., Hamilton, NJ

Clinical Manager, Clinical Trial Rater, Clinical Trial Services Department, Jan 2010 – Oct 2011
MedAvante, Inc., Hamilton, NJ

Licensed Psychologist, Sub-Investigator, Psychometric Rater, Apr 2007 – Dec 2009
CRI Worldwide, LLC, Philadelphia, PA

Licensed Psychologist and Director of Referral Services, Sept 2002 – Mar 2007
University of Pennsylvania, Counseling and Psychology Services, Philadelphia, PA

INVESTIGATOR EXPERIENCE:

Phase I • Alzheimer's Disease • Anxiety Disorder • Attention-Deficit/ Hyperactivity Disorder
Bipolar Disorder • Chronic Pain • Depression • Diabetic Peripheral Neuropathic Pain
Fibromyalgia • Insomnia • Migraine • Painful Diabetic Neuropathy • Post Herpetic Neuralgia
Schizophrenia or Schizoaffective Disorder • Sleep Disorder • Smoking Cessation

CLINICAL TRIAL EXPERIENCE:

Phase I Addiction

A Phase Ib, Randomized, Double-blind, Placebo-controlled, Ascending-dose Study of XXX to Treat Symptoms of Acute Opioid Withdrawal in Patients with Opioid Use Disorder who are Physically Dependent on Opioids

CLINICAL TRIAL EXPERIENCE (*continued*):

Phase I Depression

A Phase I/II Two-Part Study of XXX as an Adjunctive Therapy in Subjects With Major Depressive Disorder

A Phase I, Two-Part, Double-Blind, Placebo-Controlled, Twice Daily Dose Study of XXX in Adult Participants with Major Depressive Disorder (Part B)

A Phase I Randomized, Open-Label, Pilot Parallel Study To Determine The Relative Pharmacokinetic Characteristics Between XXX Versus Injectable Paliperidone Palmitate Following Different Dosing Regimens In Schizophrenia Alone Or As Use In Schizoaffective Disorders As An Adjunctive Therapy To Antidepressants

A Phase I Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Single Doses of XXX in Healthy Volunteers and Subjects with Treatment-Resistant Depression

A Phase I, Two-Part, Double-blind, Placebo-controlled, Single- and Multiple-Dose Study of XXX in Adult Participants with Major Depressive Disorder (Part A)

Phase I Healthy

A Randomized, Placebo controlled, Double-blind, Double-dummy Threeway Cross over Trial to Investigate the Effect of XXX and XXX on Ketamine-induced Cognitive Deficits in Healthy Male Subjects

A Phase I, Double-blind, Sponsor-open, Placebo-controlled, First-In-Human Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Dose of XXX in Healthy Subjects

A Phase I, Randomized, Double-blind, Placebo-controlled, Single-Ascending-Dose Trial to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Intravenous XXX in Normal Healthy Volunteers

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Combined Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXX Oral Solution in Healthy Subjects (Part B MAD)

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Combined Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXX Oral Solution in Healthy Subjects (Part A SAD)

A Phase 0, Multi-Center Study in Schizophrenic Patients and Healthy Volunteers to Validate XXX Biomarkers for Use in Therapeutic Trials

CLINICAL TRIAL EXPERIENCE (*continued*):

A Double-blinded, Placebo-controlled, Sequential Cohort, Single-dose Escalation, Phase I Study to Evaluate the Safety and Single Dose Pharmacokinetics of XXX, a Reactive Species Decomposition Accelerant, in Healthy Volunteers - A First in Human Clinical Study

A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of the Effects on Quantitative Electroencephalography and Event-Related Potential of Two Sequential Doses of XXX in Healthy Adult Males

A 2-Part, Phase I, Study of XXX Pharmacodynamics and Pharmacokinetics Alone and in the Presence of XXX or XXX

A Phase I, Randomized, Double-blind, Placebo-controlled Parallel Group Study of Multiple Doses of XXX Challenge, to Evaluate the Electrophysiology. Safety, Tolerability and Pharmacokinetics in Healthy Subjects

A Phase I Double-blind, Placebo-controlled Crossover Study of XXX Using Ketamine Challenge, to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response Using PET Imaging in Healthy Subjects

A Phase I, Double-blind, Placebo-controlled, Crossover Study of XXX Using a Ketamine Challenge to Evaluate the Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Subjects

A Phase I, Open-Label, Parallel-Group, Dose Comparison of Safety and Imaging Characteristics of XXX for Brain Imaging of Amyloid in Healthy Volunteers and Patients with Alzheimer's Disease

Phase I Schizophrenia and Schizoaffective Disorder

A Phase Ib Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of XXX in Subject with Schizophrenia

A Randomized, Single-dose, Crossover Study of the Effects of XXX on Electrocardiogram (ECG) Intervals in Subjects with Schizophrenia

A Phase I/II Study to Evaluate the Safety, Tolerability, Efficacy and effects on Neurophysiological Biomarkers of XXX Oral Treatment in Subjects with Schizophrenia and Normal Healthy Volunteers

A Phase I, Open-label, Randomized, Single Ascending Dose Trial to Determine the Pharmacokinetics, Safety, and Tolerability of XXX Long Acting Injectable in Adult Subjects with Schizophrenia

CLINICAL TRIAL EXPERIENCE (*continued*):

A Phase I, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXX for Extended-Release Injectable Suspension for Subcutaneous Use, in Healthy Subjects and in Patients with Schizophrenia or Schizoaffective Disorder

A Phase I Randomized, Open-Label, Parallel, Single-Dose Study to Evaluate the Pharmacokinetic Characteristics of XXX of Two Formulations versus INVEGA SUSTENNA® after Intramuscular Injection in Schizophrenia Patients

A Safety/Tolerance Study to Evaluate a New Titration Scheme in Patients With Bipolar I Disorder or Schizophrenia

A Phase I, Open-label, Sequential Dose Escalation Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXX Long Acting Injectable (LAI) in Subjects with Schizophrenia

A Phase I, Randomized, Double-blind, Placebo-controlled, Ascending Dose study to Determine Efficacy, Pharmacokinetic and Safety of XXX in Agitation associated with Schizophrenia or Schizoaffective Disorder

A Phase Ib, Open-label, Multiple-dose, Randomized, Parallel-arm, Safety, Tolerability, and Pharmacokinetic Trial of XXX Intramuscular Depot Administered in the Gluteal Muscle in Adult Subjects With Schizophrenia or Bipolar I Disorder

An Open-label, Single- and Multiple-dose, Pharmacokinetic, Safety, and Tolerability Trial of XXX Administered in the Deltoid or Gluteal Muscle in Adult Subjects with Schizophrenia or Bipolar I Disorder

A Phase I, Open Label, Parallel-Design, Single Dose Study to Assess the Relative Bioavailability of XXX Extended-Release Suspension for Subcutaneous Administration XXX, in Vials compared to Prefilled Syringes, in Patients with Schizophrenia or Schizoaffective Disorder

A Phase I, Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetics, Safety and Tolerability of XXX in Subjects with Schizophrenia

Phase I Other Indications

A Phase I, Multiple-Dose Study in Participants with Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXX

A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of XXX in Subjects With Irritable Bowel Syndrome Experiencing Abdominal Pain

CLINICAL TRIAL EXPERIENCE (*continued*):

A Phase I Clinical Study to Determine the Safety and Tolerability of XXX at Three Increasing Dose Levels as Add On Administration in Chronic Back-Pain Patients During Opioid Treatment

An Open label, two-part study to evaluate the impact of an improved first-time user experience on engagement with reSET and reSET-O (reSET/O) in patients with substance use disorder

A Phase I, Open-Label Study to Evaluate the Pharmacokinetics and Safety of XXX in Subjects with Impaired Hepatic Function

A Phase Ia/Ib, Dose-Escalating, Two-Part Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of XXX in Subjects with Type 2 Diabetes Mellitus

A Phase I, Single and Multiple Dose Pharmacokinetic, Tolerability and Safety Study with XXX in Pediatric Patients with Attention Deficit/ Hyperactivity Disorder

Phase II-IV

Alzheimer's Disease

A Phase II, Randomized, Double-blind, Placebo-controlled, 3-Arm Parallel Design Study to Evaluate the Effects of XXX in Patients with Early Stage Alzheimer's Disease

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of XXX in the Treatment of Agitation in Patients with Dementia, including Alzheimer's Disease

A Long-Term, Open-Label Extension Study of the Safety and Tolerability of XXX in Subjects with Alzheimer's Disease

A Phase III, Double-Blind, Randomized Study of XXX Versus Placebo When Added to Existing Stable XXX Treatment in Subjects with Mild to Moderate Alzheimer's Disease

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Pharmacodynamics/ Efficacy, Safety, Tolerability and Pharmacokinetics of 3 Fixed Dosages of XXX in Patients with Mild to Moderate Alzheimer's Disease

Anxiety Disorder

A Phase II, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Study of Two Oral Doses of XXX, with an XXX Arm, in Subjects with Generalized Anxiety Disorder

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 10-Week Study Evaluating the Efficacy and Safety of XXX for the Treatment of Generalized Anxiety Disorder

CLINICAL TRIAL EXPERIENCE (*continued*):

A Multicenter, Randomized, Double-blind Parallel-group, Placebo-controlled Study of the Efficacy and Safety of XXX Compared with Placebo as an Adjunct to Treatment in Patients with Generalized Anxiety Disorder Who Demonstrate Partial or No Response to a Selective Serotonin Reuptake Inhibitor or Seretonin-Norepinephrine Reuptake Inhibitor Alone or in Combination with Benzodiazepine

Attention-Deficit/ Hyperactivity Disorder (ADHD)

A Phase III Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of XXX in Adults with Attention Deficit/Hyperactivity Disorder

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of XXX in Adults with Attention-Deficit/ Hyperactivity Disorder (ADHD)

A Phase III, Open-label, 52-Week, Multicenter Trial Evaluating the Long-term Safety and Tolerability of XXX Sustained-Release Tablets in Adults with Attention-Deficit/ Hyperactivity Disorder

A Phase III, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy, Safety and Tolerability of XXX Sustained-release Tablets in Adults with Attention-deficit/ Hyperactivity Disorder

An Open-label, 52-Week, Multicenter Trial Evaluating the Long-term Safety and Tolerability of XXX Sustained-Release Tablets in Adults with Attention-Deficit/ Hyperactivity Disorder

A Phase II Multicenter, Fixed-Dose, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of XXX in Adult Subjects (Ages 18-55) with Attention Deficit Hyperactivity Disorder (ADHD)

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric Patients with Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction with Standard ADHD Treatment

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric Patients with Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction with Standard ADHD Treatment

A Phase II, Random, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety and Efficacy of XXX in Adult with ADHD

CLINICAL TRIAL EXPERIENCE (*continued*):

A Double-Blind, Randomized, Multi-Center, Flexible Dose Study the Efficacy and Safety of XXX in Children Aged 6-12 with Symptoms of Oppositionality and a Diagnosis of Attention-Deficit/ Hyperactivity Disorder

A Phase IV, Multi-center, Open-label Study of XXX in Pediatric Patients Ages 6-12 with ADHD

A Phase IIIb, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Efficacy and Safety of XXX in Adolescents aged 13-17 Years with Attention-Deficit/Hyperactivity Disorder with an Extension Study

Bipolar Disorder

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of XXX for 4 weeks in the Treatment of Patients with Acute Manic Episodes Associated with Bipolar I Disorder

A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled Study to determine Efficacy and Safety of Two Dose Levels of XXX in Bipolar I Disorder Patients with Acute Agitation

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of XXX in Subjects experiencing Acute Manic Episodes Associated with Bipolar I Disorder.

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed Dose Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of XXX in Patients with Bipolar I Depression

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of XXX Monotherapy in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression)

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of XXX Adjunctive to Lithium or Valproate in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression)

A Randomized, Double-Blind, Placebo-Controlled, Quetiapine-Referenced, Fixed-Dose Study of XXX in the Treatment of Depression in Patients with Bipolar I or II Disorder

A Phase II, 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed Dosage Study to Evaluate the Efficacy and Safety of XXX as Adjunctive Therapy in Adults with Major Depression Associated with Bipolar I Disorder

CLINICAL TRIAL EXPERIENCE (*continued*):

A Controlled Trial of Safety and Efficacy of XXX Versus Placebo in Patients with Bipolar Depression

A Controlled Trial of XXX versus Placebo in Patients with Bipolar Disorder in Manic or Mixed States

A Six-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible Doses of XXX as Add-On, Adjunctive Therapy with Lithium, Valproate or Lamotrigine in Bipolar Depression

A Phase III, Four-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of XXX in Bipolar I Disorder Subjects with Acute Symptoms of Mania

A Phase III, Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study of the Efficacy and Safety of XXX as Monotherapy in Adult Patients with Acute Bipolar Mania

A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of XXX in patients with Acute Mania Associated with Bipolar I Disorder

A Phase III, Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study of the Efficacy and Safety of XXX Sustained- Release as Monotherapy in Adult Patients with Acute Bipolar Depression

A Double-blind Placebo-controlled Trial of XXX and XXX in Bipolar I Disorder, Mixed Episode

A Six-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible Doses of XXX in Outpatients with Bipolar I Depression

Depression

A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of XXX in the Treatment of Adult Subjects with Major Depressive Disorder

A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of XXX in the Treatment of Adults with Major Depressive Disorder

A Phase III, Randomized, Double-Blind Study Comparing the Efficacy and Safety of XXX Plus Sertraline Versus Placebo Plus Sertraline in Adults With Major Depressive Disorder

A Phase III Randomized, Double-Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of XXX in the Treatment of Adults with Severe Postpartum Depression

CLINICAL TRIAL EXPERIENCE (*continued*):

A Phase II, 6-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group study with a Quetiapine XR arm to evaluate the efficacy, tolerability and safety of XXX in patients with Major Depressive Disorder

A Phase III, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of XXX with a Fixed, Repeated Treatment Regimen on Relapse Prevention in Adults with Major Depressive Disorder

A Phase III Open-Label Study to Assess the Long-term Safety and Efficacy of XXX in Subjects with Major Depressive Disorder

A Randomized, Double-Blind, Placebo-Controlled Trial of XXX Administered Orally to Subjects with Major Depressive Disorder

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of XXX Compared to Placebo in Adult Subjects with Comorbid Major Depressive Disorder and Insomnia

A Phase II, Multi-center, Randomized, Subject and Investigator-blinded, Placebo-controlled, Active comparator, Parallel-group Proof of Concept Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of XXX in Patient with Treatment-resistant Depression

A Phase III, Multicenter, Double-blind, Randomized, Placebo-controlled Study Evaluating the Efficacy of XXX in the Treatment of Adult Subjects with Major Depressive Disorder

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of XXX as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder.

A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study of XXX in the Prevention of Relapse in Patients with Major Depressive Disorder

A Phase III, Double-blind, Placebo-controlled Study of XXX as an Adjunct to Antidepressants in the Treatment of Patients with Major Depressive Disorder who have had an Inadequate Response to Antidepressants Alone

A Two Week, Randomized, Single-Blind, All Placebo, Pretest Posttest, Three-Part Investigation of the Efficacy of Placebo-Control Reminder Script Developed to Reduce the Place Effect

A Randomized, Double-Blind, Placebo-controlled, Multicenter Study of XXX as Adjunctive Therapy in Major Depressive Disorder

Interventional, randomized, double-blind, placebo-controlled, active reference (XXX), fixed-dose study of XXX in pediatric patients ages 12-17 years, with Major Depressive Disorder

CLINICAL TRIAL EXPERIENCE (*continued*):

A Randomized, Double-Blind, Active-Controlled Trial to Assess the Efficacy and Safety of XXX Administered Orally to Subjects with Treatment Resistant Major Depressive Disorder

A Phase IIb, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Efficacy and Safety of Adjunctive XXX in Subjects with Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of XXX in Subjects with Major Depressive Disorder

A Study of Augmentation with XXX for Patients with Major Depressive Disorder who are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, XXX-Referenced, Fixed Dose Study Comparing the Efficacy and Safety of XXX in Acute Treatment of Major Depressive Disorder in Elderly Patients

A Double-Blind, Efficacy and Safety Study on XXX Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder

A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of the Safety And Efficacy of XXX in Outpatients on Select Atypical Antipsychotics with Prominent Negative or Disorganized Thought Symptoms

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of XXX in Patients with Major Depressive Disorder

An Open-Label Study to Evaluate the Prevalence of Phenotypic Poor Metabolizers at CYP2D6 Among XXX-Treated Outpatients with Depression

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of XXX in Acute Treatment of Adults with Major Depressive Disorder

A Double-Blind, Randomized, Placebo-Controlled Study Examining the Safety, Efficacy and Tolerability of XXX in Subjects with Major Depressive Disorder (including Atypical and Meloncholic Features)

A 12-Week, Randomized, Open-Label Trial of XXX vs. Generic SSRIs in the Treatment of Severe Depressive Episode

A Double-Blind, Placebo-Controlled Study of XXX in Combination with XXX in Patients with Major Depressive Disorder

CLINICAL TRIAL EXPERIENCE (*continued*):

XXX Versus Placebo in the Long-Term Treatment of Patients with Late-Life Major Depression

A 52-week, randomized, double-blind, placebo-controlled, multi-center, parallel-group study of the long-term efficacy, tolerability and safety of XXX 25 and 50 mg in the prevention of relapse of Major Depression Disorder (MDD) following open-label treatment of 16-24 weeks

A Phase III, Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of XXX Sustained Release in Combination with an Antidepressant in the Treatment of Patients with Major Depressive Disorder with Inadequate Response to Antidepressant Treatment

XXX Versus Placebo in the Long-Term Treatment of Patients with Late-Life Major Depression

A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of XXX and Placebo in the Treatment of Unipolar Major Depressive Disorder

A Multicenter, Randomized, 24-52-Week, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of XXX Once Daily in the Prevention of Relapse of Depressive Symptoms in Outpatients with Major Depressive Disorder who Achieved an Initial Response to 12 Weeks of Open-label Treatment with XXX Once Daily

Fibromyalgia

A Randomized, Double-Blind, Placebo Controlled, Safety and Efficacy Study of XXX (XXX) in Subjects with Fibromyalgia

Migraine

A Phase III, Multicenter, Randomized, Open-label Study to Evaluate the Longterm Safety and Tolerability of Oral XXX for the Prevention of Migraine in Patients with Episodic Migraine
A Phase III, Randomized, Double blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of XXX in Migraine Prevention

A Phase III, Open-label Study of Safety and Tolerability of Chronic Intermittent Usage of XXX Nasal Spray Administered by the XXX device in Patients With Migraine Headache over 26/52 weeks

A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Combination Product Containing XXX and XXX for the Acute Treatment of Migraine in Adolescents

CLINICAL TRIAL EXPERIENCE (*continued*):

Pain

A Randomized, Double-Blind, Placebo- And Active-Controlled Study of the Safety and Efficacy of XXX in Patients with Diabetic Peripheral Neuropathic Pain

A Phase IIa, Double-Blind, Randomized, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of XXX Compared with Placebo in Patients with Painful Diabetic Neuropathy

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Tolerability of Oral XXX Versus Placebo in the Treatment of Post Herpetic Neuralgia

A Double-Blind, Randomized, Active-Controlled Crossover Study to Evaluate the Efficacy and Safety of XXX Compared with XXX for the Management of Breakthrough Pain in Opioid Tolerant Patients with Chronic Pain Followed by a 12-Week Open-Label Extension to Evaluate the Impact of XXX on Patient Outcomes

Schizophrenia or Schizoaffective Disorder

A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled Study to determine Efficacy and Safety of XXX in Agitation associated with Schizophrenia

A Phase III Extension study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension XXX for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients with Schizophrenia

A 56-week Open Label Extension to Assess Safety and Tolerability of XXX in Adult Subjects with Schizophrenia

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of XXX in Acutely Psychotic Adult Subjects with Schizophrenia

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of XXX as an Adjunctive Treatment in Adult Patients with Schizophrenia

A Phase IIIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects with Schizophrenia Treated Prospectively for 6-months with XXX

A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study to Assess the Efficacy, Safety, and Tolerability of XXX for the Treatment of Negative Symptoms of Schizophrenia

CLINICAL TRIAL EXPERIENCE (*continued*):

A Phase II, Randomized, Double-blind, Multiple-dose, Placebo-controlled Study to Evaluate the Safety and Efficacy of XXX in Subjects with Cognitive Impairment Associated with Schizophrenia (CAIS)

A Phase IIIb Double-blind, Placebo-controlled, Randomized Withdrawal Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of XXX in a Dose Reduction Paradigm in the Prevention of Relapse in Patients with Schizophrenia

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of XXX in Patients with Negative Symptoms of Schizophrenia

A Phase II Study to Assess the Safety, Tolerability, and Efficacy of XXX in Hospitalized Adults with DSM-5 Schizophrenia

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel-group Study to Assess the Safety and Efficacy of XXX as Add-on Treatment for Cognitive Impairment in Subjects with Schizophrenia on Stable Doses of Antipsychotic Medication

Interventional, Randomized, Double-Blind, Active-Controlled, Fixed-Dose study of XXX in patients with Treatment-Resistant Schizophrenia

A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, In-patient Study to Assess the Efficacy and Safety of XXX in Subjects Diagnosed with Schizophrenia

Interventional, Open-Label, Flexible-dose, Long-term safety study of XXX in adult patients with Schizophrenia

A Phase IIa, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study Designed to Determine the Safety, Tolerability and Preliminary Efficacy of an Oral Dose Range of XXX in Patients with Chronic Schizophrenia Not Responding Adequately to Their Current Antipsychotic Medication

A Phase III Study to Evaluate Weight Gain of XXX Compared to XXX in Adults with Schizophrenia

An Adaptive, Phase IIb/III, Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study of The Safety and Efficacy of XXX, A D-Amino Oxidase Inhibitor, As An Add-On Treatment for Schizophrenia in Adults

A Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of XXX After 6 Weeks of Treatment in Patients with Schizophrenia

A One Year, Open-Label, Study to Evaluate the Safety and Tolerability of XXX Implants as a Maintenance Treatment in Patients with Schizophrenia

CLINICAL TRIAL EXPERIENCE (*continued*):

An Open-Label, Multi-Center Trial to Assess the Safety and Efficacy of XXX in Patients with Schizophrenia

A 24-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of XXX as Adjunctive Therapy in Adults with Schizophrenia

A Randomized, Double-Blind, Parallel-group, Flexible-dose Study Exploring the Neurocognitive Effect of XXX Versus XXX in Patients with Schizophrenia using the MATRICS Consensus Cognitive Battery (MCCB)

A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of Three Randomized.

A Phase IIa, Multi-center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of XXX as Adjunctive Treatment in Combination with a Pre-existing Antipsychotic in Patients with Cognitive Impairment Associated with Schizophrenia

A Phase IIa, Single-Blind, Placebo-Controlled, Trial to Evaluate the Pro-Cognitive Effects of XXX in Patients with Schizophrenia

A Phase IIb, Two-Period, Two-Treatment, Open-Label Two-Way, Steady-State, Crossover Bioequivalence Study of XXX under Fasting Conditions in Patients

A Cross-Sectional, Randomized, Non-Interventions Methods Study in Clinically Stable Outpatient Subjects with Schizophrenia to Compare Approaches for Assessing Neurocognition and Functioning Endpoints

A Phase II, Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study of the Efficacy and Safety of XXX in Acutely Psychotic Subjects with Schizophrenia

A Randomized, Open-Label Study Comparing the Effects of XXX Depot with Oral XXX on Treatment Outcomes in Outpatients with Schizophrenia

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Flexible Dose XXX ER in the Treatment of Subjects with Schizoaffective Disorder

A Multi-Center, Randomized, Double-Blind, Parallel-Group Fixed-Dose Study of the Effect on Weight of XXX vs. XXX in the Treatment of Outpatients with Schizophrenia

A Multi-Center, Open-Label, Parallel-Group, Randomized, Flexible Dose Study to Evaluate the Safety and Tolerability of Switching from Existing Atypical Antipsychotics to XXX in Subjects with Schizophrenia or Schizoaffective Disorder

CLINICAL TRIAL EXPERIENCE (*continued*):

A Randomized, Multicenter, Double-blind, Parallel Group Study to Compare the Effects of XXX to XXX on Weight Changes in Stable Schizophrenic Patients

A Phase IIb, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Proof of Concept Study with 3 Oral Dose Groups of XXX during 12 Weeks Treatment of Cognitive Deficits in Patients with Schizophrenia

A Blinded-initiation Study of Medication Satisfaction in Subjects with Schizophrenia Treated with XXX after Suboptimal Response to Oral XXX

A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of Three Doses of XXX in Acutely Psychotic Patients with Schizophrenia

A Single-arm Evaluation of the Safety of XXX in Subjects with Schizophrenia or Schizoaffective Disorder with Hepatic Disease

An Open-Label, Long-Term, Multiple-Dose, Safety and Tolerability, Pharmacokinetic Study of XXX in the Treatment of Subjects with Schizophrenia

A Long-Term Safety, Tolerability and Effectiveness of XXX in Subjects with Schizophrenia or Schizoaffective Disorder: A Randomized, Active Comparator Controlled Trial

Sleep Disorders

A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of XXX as Treatment for Adults with Excessive Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome with Comorbid Major Depressive Disorder or Dysthymic Disorder

A Two-week, Double-blind, Placebo-controlled, Randomized, Parallel Group, Efficacy and Safety, Out-patient Trial with XXX in Patients with Chronic Primary Insomnia

A Phase IIb, Randomized, Double-blind, Placebo-controlled, Subjective Study to Assess the Efficacy of XXX in Patients with Primary Insomnia Characterized by Difficulty Maintaining Sleep

Smoking Cessation

A Phase II, double blind, randomized, placebo controlled, multicenter dose ranging study to assess the efficacy and safety of XXX as an aid to smoking cessation

CLINICAL TRIAL EXPERIENCE (*continued*):

Other Indications

A Phase III, Multicenter, Open-Label Trial to Evaluate the Safety and Tolerability of XXX in the Treatment of Adult Subjects with Borderline Personality Disorder

A Short-term, Multicenter, Randomized, Flexible-dose, Double-blind Trial of XXX Versus Placebo for the Treatment of Adults With Borderline Personality Disorder

A Phase III, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial of XXX (2 - 3 mg/day) as Combination Therapy with Sertraline in the Treatment of Adults with Post-traumatic Stress Disorder

A Phase I Study of Potential Treatment-Responsive Biomarkers in Hunter Syndrome

A Phase II, Sequential Parallel Comparison, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Weekly and Daily Doses of XXX in Subjects with Post-Traumatic Stress Disorder

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of XXX in Patients with Lactose Intolerance.

APhase II Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial of XXX as Monotherapy or as Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder

ADDITIONAL CLINICAL TRIAL EXPERIENCE:

From 02/2014 - 01/2016, Dr. Cohen was the Director in the Clinical Assessment Technologies Department at Worldwide Clinical Trials where he led the below studies clinically and operationally. He developed and presented scale training for these studies as the expert presenter at Investigators' Meetings, developed didactic and video scale trainings, and Quality Controlled the staff of clinicians' central review of the studies' assessment scales.

A Phase III, Double-blind, Randomized Study of XXX Versus Placebo when Added to the Existing Stable Donepezil Treatment in Subjects with Mild to Moderate Alzheimer's Disease

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study Assessing the Safety, Tolerability and Efficacy of XXX in the Treatment of Moderately Severe to Severe Alzheimer's Disease

XXX as Treatment for Major Depressive Disorder in Adult Females

ADDITIONAL CLINICAL TRIAL EXPERIENCE (*continued*):

A Phase II, 12-Week, Multicenter, Double-blind, Randomized, Placebo-controlled Parallel-group Dose Selection Study of XXX, an Oral 5-HT2C Receptor Agonist for Smoking Cessation

A Randomized Double-Blind, Placebo Controlled, Flexible Dose, Parallel Group Study of Extended-Release XXX for the Treatment of Generalized Anxiety Disorder

From 01/2010 - 01/2014, Dr. Cohen was employed at MedAvante and it is MedAvante's policy to blind all Raters from protocol information, including the title, purpose, and inclusion and exclusion criteria of all protocols. Raters are only informed of the Sponsor and study indication. Thus, as a Clinical Trial Rater and Central Reviewer at MedAvante, the following lists the study indications and respective Sponsors Dr. Cohen worked on:

-Alzheimer's disease – 2 studies
-Bipolar Depression – 1 Study
-Major Depressive Disorder – 6 Studies
-Schizophrenia – 6 Studies
-Neuropathic Pain Associated with HIV
Neuropathy – 1 Study
-Healthy Norma's – 1 Study

SCALE ADMINISTRATION/ TRAINING EXPERIENCE AS EXPERT TRAINER:

INSTRUMENT (Note: list is not intended to be exhaustive)
Abnormal Involuntary Movement Scale (**AIMS**)
Alzheimer's Disease Assessment Scale — Cognitive Subscale (**ADAS-Cog**)
Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (**ADCS-ADL**)
Attention Deficit Hyperactivity Rating Scale (**ADHD-RS—Children/Adolescents**)
Barnes Akathasia Rating Scale (**BARS**)
Beck Depression Inventory (**BDI**)
Brief Psychiatric Rating Scale (**BPRS**)
Brief Assessment of Cognition for Schizophrenia (**BACS**)
Calgary Depression Scale for Schizophrenia (**CDSS**)
Children Depression Rating Scale – Revised (**CDRS-R**)
Children's Global Assessment Scale (**CGAS**)
Clinician-Administered PTSD Scale (**CAPS-5**)
Clinical Dementia Rating Scale (**CDRS**)
Clinical Global Impression — Severity, Improvement, and Bipolar Versions (**CGI / CGI-BP**)
Clinical Validation Inventory for Study Admission (**C-VISA**)
Clinician's Interview-Based Impression of Change Plus Caregiver Input (**CIBlC-Plus**)
Clinician's Interview-Based Impression of Severity (**CIBIS**)
Columbia Suicide Severity Rating Scale (**C-SSRS**)
Cooperative Study Activities of Daily Living (**ADCS-ADL**)
Economic Assessment-Health Economic Questionnaire (**HEA**)
Generalized Anxiety Disorder w/7 Items (**GAD-7**)

SCALE ADMINISTRATION/ TRAINING EXPERIENCE AS EXPERT TRAINER (*continued*):

Geriatric Depression Scale (**GDS**)
Global Assessment of Functioning (**GAF**)
GRID Hamilton Depression Rating Scale (**GRID-HAM-D**)
Heinrichs Quality of Life Scale (**QOLS**)
Karolinska Sleepiness Scale (**KSS**)
Kiddie - Schedule for Affective Disorders and Schizophrenia (**K-SADS**)
MCCB-MATRICS Consensus Cognitive Battery
Mini International Neuropsychiatric Interview (**MINI and MINI-Plus**)
Mini-Mental Status Examination (**MMSE Versions 1 and 2**)
Minnesota Multiphasic Personality Inventory (**MMPI**)
Montgomery Asberg Depression Rating Scale (**MADRS**)
Montreal Cognitive Assessment (**MOCA**)
Negative Symptoms Assessment (**NSA-16**)
Neuropsychiatric Inventory (**NPI**)
Patient Health Questionnaire w/8 Items (**PHQ-8**)
Personal and Social Performance Scale (**PSP**)
Positive and Negative Syndrome Scale (**PANSS**)
Readiness for Work Questionnaire (**WoRQ**)
Retrospective Modified Overt Aggression Scale (**R-MOAS**)
Rosen Modified Hachinski Scale (**MHIS**)
SAFER Criteria Inventory (**SAFER**)
Scale for the Assessment of Negative Symptoms (**SANS**)
Scale for the Assessment of Positive Symptoms (**SAPS**)
Schizophrenia Cognition Rating Scale (**SCoRS**)
Severe Impairment Battery (**SIB**)
Simpson Angus Scale (**SAS**)
Structured Clinical Interview for DSM-IV Axis I Disorders (**SCID-I**)
Structured Clinical Interview for DSM IV — (clinical trials) (**SCID-CT**)
Structured Interview Guide for Global Impressions (**SIGGI**) Structured Inventory Guide for the HAM-A (**SIGH-A**) Structured Inventory Guide for the HAM-D (**SIGH-D**)
Symbol Digit Modalities Test (**SDMT**)
Thematic Apperception Test (**TAT**)
UCSD Performance-Based Skills Assessment (**UPSA**)
Vitiello Aggression Scale (**VAS**)
Verbal Fluency Test (**VFT**)
Wechsler Adult Intelligence Scale —III (**WAIS-III**)
Wechsler Intelligence Scales for Children 3rd Edition (**WISC-III**)
Wechsler Intelligence Scale for Children 4th Edition (**WISC-IV**)
Wechsler Memory Scale Revised (**WMS-R**)
Wechsler Memory Scale-Third Edition (**WMS-III**)
Wechsler Preschool and Primary School of Intelligence-Revised (**WPPSI-R**)
Wide Range Achievement Test (**WRAT-III**)
Wisconsin Card Sorting Test (**WCST**)

SCALE ADMINISTRATION/ TRAINING EXPERIENCE AS EXPERT TRAINER (*continued*):

Woodcock-Johnson Tests of Achievement (**WJTA**) Young Mania Rating Scale (**YMRS**)
10-Item Drug Attitude Inventory
36-Item Short Form Health Survey

PUBLICATIONS & PRESENTATIONS:

Cohen, E. A., Hassman, H. H., Walling, D. P., Wyka, K., Horan, W. P., Keefe, R. S., Grindell, V. M., Glass, S. J., Ball, R. R., Styczynski, J., Lobb, J. M., & Ereshefsky, L. (May, 2020). The Placebo-Control Reminder Script in depression and psychosis trials: An antidote for the placebo and nocebo response. Poster presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Miami, FL.

Hassman, H. H., Cohen, E. A., Walling, D. P., Wyka, K., Grindell, V. M., Glass, S. J., Ball, R. R., Styczysnki, J., Lobb, J. M., Hazzard-Randolph, D., Joseph, A. V., and Ereshefsky, L. (2020, April). The Placebo conundrum: Mitigating the response at the site level. Poster presented at the Annual Meeting of the Schizophrenia International Research Society (SIRS), Florence, Italy.

Cohen, E. A., Hassman, H. H., Walling, D. P., Wyka, K., Ball, R. R., Joseph, A. V., Lobb, J. M., Hazzard-Randolph, D., Ereshefsky, L., Grindell, V., Glass, S. J., Styczynski, J. (2019, November). Broadening the Empirical Exploration of the Placebo-Control Reminder Script to Reduce Placebo and Nocebo Effects: A Preliminary Data Analysis of Subjects with Schizophrenia and Schizoaffective Disorders. Poster presented at the Annual Meeting of the CNS Summit Conference, Boca Raton, FL.

Cohen, E. A., Hassman, H. H., Walling, D. P., Hoover, S., Wyka, K., Ball, R. R., Joseph, A. V., Lobb, J. M., Hazzard-Randolph, D., Ereshefsky, L. (2018, November). A first-time investigation of a subject intervention to reduce the placebo and nocebo effects: A multicenter, randomized, single-blind, all placebo study of a Placebo-Control Reminder Script for subjects with Major Depression. Poster presented at the Annual Meeting of the CNS Summit Conference, Boca Raton, FL.

Hassman, H., Cohen, E.A., Ball, R.R., Joseph, A.V., Wyka K., Lobb, J.M., & Ereshefsky, L., (2018, February). Can subjects with Major Depression learn about key placebo response factors? The effect of an educational placebo response video. Poster presented at the Annual Meeting of the International Society for CNS Clinical Trials and Methodology Conference, Washington, DC.

Hassman, H., Cohen, E. A., Myers, K. A., Hossain, S. I, Joseph, A. V., & Lobb, J. M. (2017, November). The Power of an Educational Placebo Response Video: Strengthening Subject Placebo Response Awareness Across Demographic Variables and Diagnoses. Poster presented at the Annual Meeting of the CNS Summit, Boca Raton, FL.

PUBLICATIONS & PRESENTATIONS (*continued*):

Hassman, H., Cohen, E., Hossain, S., Amerman, P.M., Joseph, A.V., & Myers, K.A., (2017, May). Enhancing subjects' awareness of key placebo response factors: The importance of implementing a brief educational placebo response video. Poster presented at the Annual American Society of Clinical Pharmacology, Miami, FL.

Lytle, D., Cohen, E. A., Rock, C. R., Komorowsky, A. E., Friedmann, B., & Murphy, M. F. (2016, February). Obtaining a more comprehensive understanding of site and subject preferences for clinical assessment technologies: Key implications for the industry. Poster presented at the Annual International Society for CNS Clinical Trials and Methodology Conference, Washington, DC.

Lytle, D., Cohen, E. A., Rock, C. R., Komorowsky, A. E., Friedmann, B., & Murphy, M. F. (2015, October). Understanding site preferences with eCOA technologies used to increase the reliability of clinical assessments: A multi-national study. Poster presented at the Annual CNS Summit Meeting, Boca Raton, FL.

Baldwin, F., Avrumson, R., Cohen, E. A., Friedmann, B., Carbo, M. A., Glaug, N. C., Komorowsky, A. E., Rapsomaniki, E., Rock, C. R., & Murphy, M. F. (2015, October). Examining the impact of ongoing assessment feedback on site rater performance: Does our work matter? Poster presented at the Annual CNS Summit Meeting, Boca Raton, FL.

Cohen, E. A., Friedmann, B., Hrevatis, D., & Murphy, M. F. (2014, November). Conceptual and methodological implications of brief unidimensional subscales in antidepressant clinical trials. Poster presented at the Annual CNS Summit Meeting, Boca Raton, FL.

Cohen E.A., Avrumson, R., Friedmann, B., Baldwin, K. F., Carbo, M. A., Glaug, N. C., Komorowsky, A. E., Meighan, S. P., Perrett, J. H., Rock, C. R., & Murphy, M. F. (2015, June). US and Eastern and Central European rater performance administering the Mini International Neuropsychiatric Interview (MINI): Are there implications for training and sponsor global site selection? Poster presented at the Annual American Society of Clinical Psychopharmacology, Miami, FL.

Friedmann, B., Cohen, E. A., Abraham, J,m & Murphy, M. F. (2014, November). Investigator roles in clinical trials. Poster presented at the Annual CNS Summit Meeting, Boca Raton, FL.

Williams, J. B. W., Hannesdottir, K., Randolph, C., Eureyecko, E., Langbaum, J., Tariot, P., Farlow, M., Galvin, J., Langlois, C., Hunt, C., Olsson, T., Poole, M., Weber, C., Boehm, P., Cohen, E. A., Carzio, L. M., & Alexander, R. (2014, July). Telephone administration of the CDR — Excellent agreement with face-to-face administration. Poster session presented at the Annual Alzheimer's Association International Conference, Copenhagen, Denmark.

PUBLICATIONS & PRESENTATIONS (*continued*):

Williams, J. B. W., Popp, D., Osman, D. A., Cohen, E. A., & Detke, M. J. (2012, February). The evaluation of negative symptoms by videoconferencing in a clinical trial. Poster session presented at the Annual International Society for CNS Clinical Trials and Methodology Conference, Washington, DC.

Popp, D., Williams, J. B. W., Cohen, E. A., & Detke, M. J. (2012, April). NSA-16 revisited: Identifying latent factors of negative symptoms in schizophrenia. Poster session presented at the biennial meeting of the Schizophrenia International Research Conference, Florence, Italy.

Williams, J. B. W., Popp, D. Osman, D. A., Cohen, E. A., & Detke, M. J. (2012. April). The use of the NSA16 by videoconferencing in a clinical trial. Poster session presented at the biennial meeting of the Schizophrenia International Research Conference, Florence, Italy.

Johnson, T. J., & Cohen, E. A. (2004). College students' reasons for not drinking and not playing drinking games. Substance Use and Misuse, 39 (7), 1137-1160.

Cohen, E. A., Vasey, M. W., & Gavazzi, S. M. (2003). The dimensionality of family differentiation and the prediction of adolescent internalized distress. Journal of Family Issues, 24, 99_23.

Stanley, J., Cohen, E. A., Wolgast, B., & Goldberg, A. (2003, March). Psychotherapy efficacy for LGBTQ college students. Paper to be presented at the annual meeting of the Eastern Psychological Association, Baltimore, MD.

Cohen, E. A. (2003, March). Making choices: The gav man's resolution to improve his body image. Invited workshop presentation for the annual meeting of the Guidance for Understanding Image Dieting and Eating Association, Philadelphia, PA.

Goldberg, A. L., Wolgast, B., Cohen, E. A., & Stanley, J. (2002, August). Outing outcome research: Psychotherapy findings for Lesbian, Gay. Bisexual, Transgender, and Questioning College Students. Poster session to be presented at the annual meeting of the American Psychological Association, Chicago, IL.

Cohen, E. A. (2002, March). 'Coming Out' of judging one's own body image. Invited workshop presentation for the annual meeting of the Guidance for Understanding Image Dieting and Eating Association, Philadelphia, PA.

Santiago, A., Henderson, H. J., Grigar, M. E., & Cohen, E. A. (2000, August). A phenomenological evaluation of a multicultural graduate student support group. Symposium conducted at the annual meeting of the American Psychological Association, Washington, DC.

Huffey, B., Cohen, E. A., Richardson, T., Santiago, A., & Mailloux, S. (1999, October). A night at the improv: Dream work in group supervision. Symposium conducted at the annual meeting of the Association for Counselor Education and Supervision, New Orleans, LA.

PUBLICATIONS & PRESENTATIONS (*continued*):

Boyer, M. C., Cohen, E. A., Schultz, T., McIntyre, J., Evans, L., Ajmere, K., & Coleman, C. L. (1999, August). Relating religion and spirituality: Obtaining clarity for the counseling profession. Poster presented at the annual meeting of the American Psychological Association, Boston, MA.

Boyer, M. C., Ajmere, K., McIntyre, J., & Cohen. E. A. (1999, April). White racial consciousness: A first look at demographics. Poster presented at the annual meeting of the American Psychological Association's Division 17 Great Lakes Conference, Columbus, OH.

Huffey, B., Santiago, A., Richardson, T., Mailloux, S., & Cohen, E. A. (1999, April). Dream work: Innovative supervision for the new millennium. Symposium conducted at the annual meeting of the American Psychological Association's Division 17 Great Lakes Conference, Columbus, OH.

Boyer, M. C., Cohen, E. A., Ajmere, K., Alexander, N., McIntyre, J., & Schultz, T. (1999, March). Spirituality and religion: The therapist's kaleidoscope. Structured discussion presented at the annual meeting of the Association for Women in Psychology Conference, Providence, RI.

Boyer, M. C., & Cohen, E. A. (1999, February). Self-care: It's FUNdamental! Workshop presented at the annual meeting of the Indiana Counseling Association Conference, Indianapolis, IN.

Predina, L. A., Zehr, M., Gridley, B. E., & Cohen, E. A. (1998, April). The Gender-Neutral Rape Scale. Poster presented at the annual meeting of the American Psychological Association's Division 17 Great Lakes Conference, Bloomington, IN.

Boyer, M. C., Kelly, K. T., Lash, J. M., Schmidt, S. R., & Cohen, E. A. (1998, March). Psvchological and spiritual passages in therapy: In search for calm seas. Structured discussion presented at the annual meeting of the Association for Women in Psychology Conference, Baltimore, MD.

Cohen, E. A., & Boyer, M. C. (1998, March). Unchartered cross-cultural territory: Relating White racial consciousness to religiosity and spirituality. Poster presented at the annual meeting of the Association for Women in Psychology Conference, Baltimore, MD.

Cohen, E. A., Ajmere, K., & Juarez-Cullen, M. (1997, April). The incredible adventures of two counseling trainees facilitating diversity outreach: A phenomenological evaluation. Poster presented at the annual meeting of the American Psychological Association's Division 17 Great Lakes Conference, Kalamazoo, Ml.

Cohen, E. A. (1996, April). A review of the empirical literature on codependency and its application to counseling. Paper presented at the annual meeting of the American Psychological Association's Division 17 Great Lakes Conference, Muncie, IN.

PUBLICATIONS & PRESENTATIONS (*continued*):

Predina, L. A., Cohen, E. A., Zehr, M., Stachula, J., & Gridley, B. (1996, April). Counselor-in-training attitudes toward different rape scenarios: A manipulation of the victim and rapist's gender. Poster presented at the annual meeting of the American Psychological Association's Division 17 Great Lakes Conference, Muncie, IN.

Serafica, F. C., & Cohen, E. A. (1995, June). Socialization and occupational identity development: Filipino Americans in national and transnational contexts. Paper presented at the annual meeting of the American Association for Asian American Studies, Oakland, CA.